Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory B cell precusor (BCP) Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) who have received no prior salvage treatment for relapsed / refractory (R/R) disease and are considered eligible for transplant (e.g., as a bridge-to-transplant).
This is written in the approval document as:
Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | BCR::ABL1 | Acute Lymphoid Leukemia | Blinatumomab |